Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03516617
Title Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Acalabrutinib

Acalabrutinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.